^
    6ms
    Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=62, Completed, CARsgen Therapeutics Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Sep 2023
    Trial completion • Trial completion date
    |
    CLDN18 (Claudin 18)
    |
    capecitabine • oxaliplatin • AB011
    almost2years
    Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, CARsgen Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | N=197 --> 62 | Trial primary completion date: Dec 2022 --> Jul 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    capecitabine • oxaliplatin • AB011
    almost2years
    A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors. (ASCO-GI 2023)
    These results indicate that AB011, either in monotherapy or combined with chemotherapy, had a manageable safety profile and encouraging efficacy in CLDND18.2 positive advanced GC/GEJA and PC. Clinical trial information: NCT04400383.
    Clinical • P1 data • Metastases
    |
    CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
    |
    CLDN18.2 expression • CLDN18.2 positive
    |
    capecitabine • oxaliplatin • AB011
    almost3years
    Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=197, Recruiting, CARsgen Therapeutics Co., Ltd. | N=103 --> 197 | Trial primary completion date: May 2022 --> Dec 2022
    Enrollment change • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    AB011